Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
What's the company's book value, and why would someone loan over $10 million in a biotech firm that hasn't generated revenue in over 15 years? What if everything goes wrong and the company goes bankrupt? How would the financier recoup their investment? It suggests that the financier has confidence in the company and its management.
I hope nwbo is paying attention. This is how you role out an acceptance. You tag it with a manufacturing giant, and your stock pops another 13%.
ImmunityBio has signed an exclusive global arrangement with the Serum Institute of India to supply ImmunityBio with Bacillus Calmette-Guerin
16:07:20 PM ET, 05/02/2024 - Briefing.com
Collaboration will result in BCG manufacture at large scale for use in combination with ANKTIVA, ImmunityBio's recently approved treatment for non-muscle invasive bladder cancer.Serum Institute of India will manufacture both standard BCG and next-generation recombinant BCG, creating a long-term solution to chronic BCG supply shortage issues.Standard BCG from the Serum Institute is currently administered in number of countries worldwide for treatment of NMIBC.Recombinant BCG has demonstrated potent immunogenicity with CD8+ and CD4+ stimulation and improved safety compared to standard BCG in clinical trials across Europe.Collaboration will help to ensure availability of BCG for all approved indications that benefit from ANKTIVA's triangle offense of natural killer cells, T cells, and memory T cells.Global clinical trials planned to study standard of care ANKTIVA plus BCG with globally available sBCG and iBCG from Serum Institute, the QUILT BCG randomized clinical trial.
Did you genuinely invest in this company? Just curious.
What a joke. She diluted the crap out of the shareholders for the past 4 months and now does a loan for 11 million.
securing private financing is advantageous, as it avoids diluting stock, and typically leads to a rise in stock value. However, our situation is unique. Let's wait and see what unfolds tomorrow...
3-4 months will mean few months to most people . So esp while talking about NWBO , several likely means much more than that
How well Posner et al pleas is only as good as the integrity, quantitative skills, and fidelity this Judge has for his oath that will decide, whether or not he grants the MTD. As far as I know, we haven't seen any of these market makers moved to discovery, correct? It won't be the first time, that sound legal minds feel confidence in a case, only to be blindsided by the courts decision later. What I do know is this. 25% of the Federal Circuit is captured and controlled through blackmail. Are the Judges in our case among the 25% or 75%? Wasn't there a magistrate change or something earlier in this case? If a Judge is controlled, he's certainly going to be crafty, and not telegraph his intentions. He may minimize the fall out, as we've only seen an appetite to get to the bottom of 30 * transactions.
Investor082, November 10, 2023. First payment not due until 11/24. Prepayment with a 10% charge. Proceeds used for "the Company’s ongoing business operations."
https://www.sec.gov/ix?doc=/Archives/edgar/data/0001072379/000110465923119165/tm2330851d1_8k.htm
the company says alot of things that prove to be hogwash.
Thanks. When was that 2023 loan initiated roughly that had prepayment penalty?
More C shares in the printing press!!!
Salaries and bonuses need to get funded.
Similarly, one does not assert that the funds will be used to increase manufacturing capacity of a product pending MAA review when one is in possession of an insurmountable RFI and when asserting 'ongoing business operations' will do.
Let’s see if SP hopefully starts going up
Great point and agree 100%.
Looking forward to seeing the Flaskworks "EDEN" unit up set up in their respective clean rooms.
The Flaskworks units are highly automated and will be able to be both monitored and controlled from a
single source central control center. In addition, each Flaskworks unit has the capability to adapt to
its optimal manufacturing specifications. The question is if the software team will incorporate IA processes to provide additional control and flexibility, IMPO?
One doesn’t spend for commercial Eden facility expansion at this point and time unless one is confident in approval and the approaching need to ramp for further UK demand. IMO, it’s that simple.
What a read! LOL.
Wow, how long have you been thinking about that post. LOL
So, you now admit that governance reforms were demanded. Good.
SB...I forget all the details. Did LL operate on her then provide ALT?
2023 loan did but previous loans did not have prepayment penalty. The lender believes company will be able to access financing on far better terms. Approval anytime!
Anyone knows if their previous loan agreement with Streeterville included prepayment penalty?
Good for Advent.
At some point they'll exchange the senior debt for some new class along with a likely reverse split.
>>The Loan Agreement contains customary default provisions, including for potential acceleration.
learningcurve2020,
First Lady Bayh had brain cancer. Do you know the specifics about that cancer genotype, how much was actually resected and stored properly that could have potentially been used to make vaccine which would guide on best path forward as well as whether or not DCVax-L was fully available to her at that time? Accusing is easy, backing the accusation up with solid evidence not so much. Come back with all the details if you can even get access to them. Best wishes.
From 2/06/24 NWBO PR:
Looks like the Flaskworks units haven't been delivered yet, but will be soon:
$NWBO New loan. I like the use of proceeds as it indicates manufacturing/business confidence: "The funds will be used for the Company’s ongoing business operations, including beginning initial construction works for the first grade C lab in the Company’s Sawston, UK facility,…
— Cesar Urrea (@Tijero) May 2, 2024
Always seemed likely to me that pseudo was going to the L arm. Nobody here ever wants to discuss it.
Great advice as many have placed you on the ignore list and thus a fool.
A fool for fabricating and mis leading NWBO investors while knowing that NWBO is
making great forward progress, IMPO.
Citadel spewing recycled garbage
Good news for Northwest's lawsuit, bad news for the soon to be "Bunk Muffins"!!!
⚖️Defendants’ Joint Memorandum of Law in Support of Motion to Dismiss Second Amended Complaint (“MTD”)⚖️$NWBO
— hoffmann6383 (@hoffmann6383) May 2, 2024
Yesterday the Defendant Market Makers in the NWBO spoofing case filed their MTD NWBO's Second Amended Complaint.
The Case: Northwest Biotherapeutics, Inc v. Canaccord…
Inquirig,
“If they are wise, do not quarrel with them; if they are fools ignore them”- - - Epictetus (Quoted by Inquirig)
You have given several here a great compliment by your inability to ignore us even though you lack the discipline not to quarrel; ). Thank you. Best wishes.
“Apple Announces $110 Billion Buyback”
Someone tell Les to call Apple…
First of all I didn't accuse you of braking any laws. Indirectly I accused you of wasting people's time which you do with great frequency.
As far as my cost basis, I am a relatively newcomer to NWBO so my cost basis is just fine. Thanks for being concerned.
8K filed 5/2:
https://www.sec.gov/ix?doc=/Archives/edgar/data/0001072379/000110465924056424/tm2413348d1_8k.htm
Item 1.01. Entry into a Material Definitive Agreement.
Loan Entered Into
On April 26, 2024, Northwest Biotherapeutics, Inc. (the “Company”) entered into a Commercial Loan Agreement and Note (collectively, the “Loan Agreement”) with Streeterville Capital, LLC (the “Holder”) in the amount of $11,005,000. The Loan Agreement has a maturity of 22 months. Repayments do not start until December 26, 2024.
Following December 26, 2024, the Loan Agreement will be amortized in 14 equal monthly installments of principal at 110% of the pro rata amount, plus accrued interest. Interest on the Loan Agreement accrues at a rate of 8% per annum, and the Loan Agreement includes an original issue discount of ten percent. The Loan Agreement allows pre-payment at any time at the Company’s election. If the Company elects to pre-pay, the pre-payment would include a 10% charge. The Loan Agreement contains customary default provisions, including for potential acceleration.
The funds will be used for the Company’s ongoing business operations, including beginning initial construction works for the first grade C lab in the Company’s Sawston, UK facility, ordering certain initial long lead-time equipment for the first grade C lab, and facility preparations for delivery of the initial GMP units of the Flaskworks system.
https://www.sec.gov/ix?doc=/Archives/edgar/data/0001072379/000110465924056424/tm2413348d1_8k.htm
iclight,
No, I clearly stated Linda has options. You see while you clearly try hard to create resentment towards Linda Powers she is clearly working hard to get L then Direct to patients and that has included working closely with MHRA to move from artisan to more automated and enclosed manufacturing. This is obviously so stricter product release standards in the UK and EU can be met first before any other approval. This makes approvals elsewhere much easier to achieve, especially in the US where heavy influence from big pharma on FDA clearly exists but can be countered with demand from patients for treatment.
Mischaracterizing the motives of Linda Powers and others is what you do. Fortunately longs are for the most part not buying into the false light your perspective comes from because the truth here is more than sufficient to convince without taking a bite out of what you have to offer; ). Best wishes.
Streeterville…lol
If they had had a serious banker, we would have seen high-profile investors.
Oh boy…
The funds will be used for the Company’s ongoing business operations, including beginning initial construction works for the first grade C lab in the Company’s Sawston, UK facility, ordering certain initial long lead-time equipment for the first grade C lab, and facility preparations for delivery of the initial GMP units of the Flaskworks system.
Attempts to misdirect and steal thunder are always noticed, thank you very much.
That ought to help people have confidence that the stock market is totally on the up-and-up, and not that the premise of 'ownership' of a company through common stocks is 75% scam.
Despite your deep desire to MISDIRECT, what all the shorts do around here… your fraud is obvious.
The brash move is a sign of guilt. It's pure posturing to appear to be a victim.
DD - GREAT POST 📯📯📯💎🙌
She's right... But NWBO is still going to zero IMO-
Yes to what she opined... .... oh and by the way she works for UCLA.... Only gets paid by you bag holders for credibility of the OTCBB stock scam...
Wise up son... You have been had.
All posts are my opinions
Just like death on DCVax. Inevitable.
Followers
|
1626
|
Posters
|
|
Posts (Today)
|
199
|
Posts (Total)
|
692393
|
Created
|
02/02/05
|
Type
|
Free
|
Moderators XenaLives sentiment_stocks CaptainObvious Poor Man - Doc logic JerryCampbell |
“Now this is not the end. It is not even the beginning of the end. But it is, perhaps, the end of the beginning.”
~ Winston Churchill
Stylized Dendritic Cell featured on NWBO board since 2015
- Dr. Linda Liau, PhD, MBA, Professor and Chair, Department of Neurosurgery, David Geffen School of Medicine at UCLA
Clinical Trials
DCVax®-L to Treat Newly Diagnosed GBM Brain Cancer (NCT00045968) - Phase III (Double Blind)
UK (MHRA): DCVax-L to Treat Newly Diagnosed GBM Brain Cancer (EudraCT#) 2011-001977-13
DE (Germany - PEI): DCVax-L to Treat Newly Diagnosed GBM Brain Cancer (EudraCT#) 2011-001977-13
Expanded Access Protocol for GBM Patients with Already Manufactured DCVax®-L Who Have Screen-Failed Protocol 020221 (NCT02146066) (Expanded Access)
Safety and Efficacy Study of DCVax-Direct in Solid Tumors (NCT01882946) - Phase I/Phase II (Open Label)
UK Clinical Trials - Study of a Drug (DCVax®-L) to Treat Newly Diagnosed GBM Brain Cancer
EU Clinical Trials for DCVax-L - Phase III
Dendritic Cell Vaccine for Patients with Brain Tumors (NCT01204684) - Phase II - at UCLA - Randomized (Open Label) testing DCVaccine with Resiquimod and DC Vaccination with Adjuvant polyICLC
Pembrolizumab and a Vaccine (ATL-DC) for the treatment of Surgically Accessible Recurrent Glioblastoma - Phase 1 (NCT04201873)
Dendritic Cell-Autologous Lung Tumor Vaccine (DCVax-L) and Nivolumab in Treating Patients with Recurrent Glioblastoma - Phase 2 (NCT03014804)
Dendritic Cell Therapy for Brain Metastases From Breast or Lung Cancer (NCT0368765) - Phase 1 - Collaborator: Mayo Clinic
Announcement of DCVax-L and Anti-PD-1 Monoclonal Antibody (Pembrolizumab) for Patients with Liver Metastases of Primary Colorectal Carcinoma Phase 2 Trial - November 17, 2016 - University Medical Center (UMC) of the Johannes Gutenberg University of Mainz
Cognate Bioservices - Owned by Charles River Labs
Website
Company Contact Info
Investor Relations:
Les Goldman (Company) (202) 841-7909 lgoldman@nwbio.com
Sign up for Northwest email list here (hit the subscribe to email list button in the lower right)
Company Headquarters
4800 Montgomery Lane, Suite 800, Bethesda, MD 20814 (240) 497-9024
NW Bio is developing cancer vaccines designed to treat a broad range of solid tumor cancers more effectively than current treatments, and without the side effects of chemotherapy drugs. NW Bio’s proprietary manufacturing technology enables them to produce its personalized vaccine in an efficient, cost-effective manner. NW Bio has a broad platform technology for DCVax dendritic cell-based vaccines.
Their lead product, DCVax-L, is currently in a 331-patient Phase III trial for patients with newly diagnosed Glioblastoma multiforme (GBM), the most aggressive and lethal brain cancer. This trial is currently underway at 69 locations thoughout the United States, Germany and the United Kingdom. NW Bio has also conducted a Phase I/II trial with DCVax-L for late stage ovarian cancer together with the University of Pennsylvania.
Their second product, DCVax-Direct, is currently in a 60-patient Phase I/II trial for direct injection into all types of inoperable solid tumor cancers, with trials currently being conducted at both MD Anderson Cancer Center in Texas, as well as Orlando Health in Florida.
They previously received clearance from the FDA for a 612-patient Phase III trial with its third product, DCVax-Prostate, for late stage prostate cancer.
DCVAX Survival Stories & Testimonials
Alice - Metastic Merkel Cell patient from Florida - ASCO 2018
Brad Silver - GBM patient from Huntington Beach, California - ASCO 2018
Sarah Rigby - GBM patient from Hong Kong - ASCO 2018
Kristyn Power - daughter of GBM patient from Canada - ASCO 2018
Kat Charles - GBM patients from UK - ASCO 2018 - as related by her husband Jason (Kat's Cure)
Prospective patients may contact NW Bio at patients@nwbio.com
UCLA Jamil Newirth DCVax-Patient Video - 2015
Allan Butler Video - National Geographic Vice President - DCVax-Direct patient from Phase 1 Trial with Pancreatic Cancer
NWBO - Patients Sunday Dennis and Jami Newirth - Enrolled at UCLA - Vimeo, Uploaded approx. May 2015
NWBO - Vaccine Helps Keep Brain Cancer Patient Alive (Jennifer Sugioka) - NBC Channel 4, Southern California, February 24, 2015
NWBO - National Geographic's Allan Butler Stage IV Pancreatic Patient using DCVax-Direct at MD Anderson
NWBO GBM Brain Cancer Survival Story of Mark Pace
Presentations
UCLA Agreements
Prostrate
DCVax-Phase II
DCVax-Booster
Upcoming Events
Videos
Linda M. Liau, MD, PhD, MBA - April 24, 2019 at University of Washington, Neurosciences Institute
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |